Clearing the MIST (metabolites in safety testing) of time: The impact of duration of administration on drug metabolite toxicity.

[1]  P. Hainaut,et al.  Hepatocellular carcinoma: from gene to public health. , 1997, Journal of the National Cancer Institute.

[2]  R. Doll,et al.  Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. , 1978, Journal of epidemiology and community health.

[3]  K. Steenland,et al.  Cancer, heart disease, and diabetes in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. , 1999, Journal of the National Cancer Institute.

[4]  M. Lippmann,et al.  Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. , 2004, Chest.

[5]  Boelsterli Ua.  Nimesulide and hepatic adverse effects: roles of reactive metabolites and host factors. , 2002 .

[6]  R. Montesano,et al.  Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. , 2006, Carcinogenesis.

[7]  R. Frye,et al.  Debilitating Reaction following the Initial Dose of Tramadol , 1997, The Annals of pharmacotherapy.

[8]  J. Pellock,et al.  Felbamate in Epilepsy Therapy , 1999, Drug safety.

[9]  Nicholas Moore,et al.  Patterns and correlates of benzodiazepine use in the French general population , 2004, European Journal of Clinical Pharmacology.

[10]  D. Graham,et al.  Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. , 2003 .

[11]  P Grasso,et al.  Dose and time relationships for tumor induction in the liver and esophagus of 4080 inbred rats by chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine. , 1991, Cancer research.

[12]  L. Weinrauch,et al.  A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. , 1998, The New England journal of medicine.

[13]  L. Mandell,et al.  Comparative Tolerability of the Newer Fluoroquinolone Antibacterials , 1999, Drug safety.

[14]  R Scott Obach,et al.  SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING , 2005, Drug Metabolism and Disposition.

[15]  P. Infante.  Benzene Exposure and Multiple Myeloma , 2006, Annals of the New York Academy of Sciences.

[16]  S. Knowles,et al.  Rapid Onset of Risperidone-Induced Hepatotoxicity , 1998, The Annals of pharmacotherapy.

[17]  P. Watkins,et al.  Tolcapone: An Efficacy and Safety Review (2007) , 2007, Clinical neuropharmacology.

[18]  Paul B. Watkins,et al.  Clinical Pattern of Zileuton-Associated Liver Injury , 2007, Drug safety.

[19]  S. Rodenhuis,et al.  Clinical Pharmacokinetics of Cyclophosphamide , 1979, Clinical pharmacokinetics.

[20]  B. Kang,et al.  Long‐term patient monitoring for clozapine‐induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS? , 2006, Human psychopharmacology.

[21]  D. Smith,et al.  A mortality study of vinyl chloride monomer workers employed in the United Kingdom in 1940-1974. , 1988, Scandinavian journal of work, environment & health.

[22]  C. Kwoh,et al.  Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. , 1995, Arthritis and rheumatism.

[23]  P. Schulte,et al.  DNA hyperploidy as a marker for biological response to bladder carcinogen exposure , 1988, International journal of cancer.

[24]  Esther F. Schmid,et al.  Drug withdrawals and the lessons within. , 2006, Current opinion in drug discovery & development.

[25]  P. Guénel,et al.  Leukemia in relation to occupational exposures to benzene and other agents: a case-control study nested in a cohort of gas and electric utility workers. , 2002, American journal of industrial medicine.

[26]  L. Naldi,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.

[27]  Jesper Hallas,et al.  Templates for analysis of individual-level prescription data. , 2006, Basic & clinical pharmacology & toxicology.

[28]  M. Thun,et al.  Lung cancer mortality is related to age in addition to duration and intensity of cigarette smoking: an analysis of CPS-I data. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[29]  R Scott Obach,et al.  Metabolites and safety: What are the concerns, and how should we address them? , 2006, Chemical research in toxicology.

[30]  A. Monro,et al.  High dose levels are not necessary in rodent studies to detect human carcinogens. , 1993, Cancer letters.

[31]  R. Fleming.  An Overview of Cyclophosphamide and Ifosfamide Pharmacology , 1997, Pharmacotherapy.

[32]  D. Williamson,et al.  Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy , 1999, International Journal of Obesity.

[33]  Ken Takahashi,et al.  Estimating the Induction Period of Pleural Mesothelioma From Aggregate Data on Asbestos Consumption , 2003, Journal of occupational and environmental medicine.

[34]  L. Laine,et al.  A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience , 2006, Pharmacoepidemiology and drug safety.

[35]  Michael J Thun,et al.  Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. , 2003, Cancer research.